Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study (2018) Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, et al. Conference contribution Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms (2018) Apostolidis L, Kreutzfeldt S, Oles M, Gieldon L, Heining C, Horak P, Hutter B, et al. Conference contribution Survival-associated factors and a prognostic nomogram in resected pancreatic cancer: A large international population-based cohort study (2018) Huang L, Balavarca Y, Van Der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, et al. Conference contribution Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018) Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al. Conference contribution Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018) Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study (2018) Hecht M, Hahn D, Wolber P, Hautmann M, Reichert D, Weniger J, Belka C, et al. Conference contribution COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET (2018) Pavel ME, Rinke A, Baum RP Conference contribution A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018) Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al. Conference contribution Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) Roellig C, Kramer M, Gabrecht M, Haenel MH, Herbst R, Kaiser U, Schmitz N, et al. Journal article Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) Nabieva N, Kellner S, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, et al. Journal article